This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

6 candidates mapped to SDH-deficient disease pathways

All (38)established (6)clinical trial (5)preclinical (14)theoretical (13)
Belzutifan

Welireg

established

HIF-2α inhibitor

Hif Pseudohypoxia
All SDH tumors
Evidence Score
88
FDA Approved1 trial
Sunitinib

Sutent

established

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt
GISTPPGL/PCCRCC
Evidence Score
78
FDA Approved1 trial
Bevacizumab

Avastin

established

Anti-VEGF monoclonal antibody

Vegf Signaling
PPGL/PCC
Evidence Score
65
FDA Approved
Cabozantinib

Cabometyx, Cometriq

established

Multi-kinase inhibitor (VEGFR2/MET/AXL/RET/KIT)

Hif Met Axl SignalingVegf Signaling
PPGL/PCCRCC
Evidence Score
62
FDA Approved2 trials
Regorafenib

Stivarga

established

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k Akt
GISTRCC
Evidence Score
58
FDA Approved
Lutetium-177 DOTATATE

Lutathera

established

Peptide receptor radionuclide therapy (PRRT) / SSTR2-targeted radioligand therapy

Sstr2 Somatostatin VulnerabilitySdh Driven Hrd
PPGL/PCC
Evidence Score
35
FDA Approved3 trials